NanoViricides, Inc. (NNVC)
1.14
-0.03
(-2.56%)
USD |
NYAM |
Nov 20, 16:00
1.14
0.00 (0.00%)
After-Hours: 20:00
NanoViricides Enterprise Value : 26.55M for Nov. 20, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 20, 2026 | 26.55M |
| November 19, 2026 | 27.32M |
| November 18, 2026 | 27.83M |
| November 17, 2026 | 27.07M |
| November 16, 2026 | 29.11M |
| November 13, 2026 | 28.85M |
| November 12, 2026 | 31.92M |
| November 11, 2026 | 32.69M |
| November 10, 2026 | 33.71M |
| November 09, 2026 | 31.41M |
| November 06, 2026 | 31.15M |
| November 05, 2026 | 30.39M |
| November 04, 2026 | 32.69M |
| November 03, 2026 | 33.96M |
| November 02, 2026 | 31.92M |
| October 30, 2026 | 31.41M |
| October 29, 2026 | 33.96M |
| October 28, 2026 | 34.48M |
| October 27, 2026 | 34.73M |
| October 26, 2026 | 32.18M |
| October 23, 2026 | 33.20M |
| October 22, 2026 | 32.94M |
| October 21, 2026 | 36.01M |
| October 20, 2026 | 35.24M |
| October 19, 2026 | 30.64M |
| Date | Value |
|---|---|
| October 16, 2026 | 32.69M |
| October 15, 2026 | 32.43M |
| October 14, 2026 | 30.90M |
| October 13, 2026 | 31.15M |
| October 12, 2026 | 30.13M |
| October 09, 2026 | 30.64M |
| October 08, 2026 | 30.90M |
| October 07, 2026 | 34.22M |
| October 06, 2026 | 33.20M |
| October 05, 2026 | 34.48M |
| October 02, 2026 | 30.13M |
| October 01, 2026 | 29.62M |
| September 30, 2026 | 30.64M |
| September 29, 2026 | 27.12M |
| September 28, 2026 | 31.72M |
| September 25, 2026 | 30.34M |
| September 24, 2026 | 30.34M |
| September 23, 2026 | 31.95M |
| September 22, 2026 | 32.41M |
| September 21, 2026 | 36.09M |
| September 18, 2026 | 29.88M |
| September 17, 2026 | 29.42M |
| September 16, 2026 | 24.82M |
| September 15, 2026 | 21.36M |
| September 14, 2026 | 21.36M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| ACADIA Pharmaceuticals, Inc. | 2.052B |
| Alnylam Pharmaceuticals, Inc. | 18.66B |
| Anika Therapeutics, Inc. | 158.39M |
| Savara, Inc. | 776.30M |
| Arrowhead Pharmaceuticals, Inc. | 6.053B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -5.743M |
| Total Expenses (Quarterly) | 5.743M |
| EPS Diluted (Quarterly) | -0.2317 |
| Earnings Yield | -46.96% |
| Normalized Earnings Yield | -46.96 |